SecBot SecBot
8-K ·Filed Aug 5, 2026

ABBV

AbbVie Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago SEC0001104659-26-091269
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor the closing of the Apogee Therapeutics acquisition and any subsequent rating agency actions on AbbVie's credit profile following the debt-funded deal. The large bond issuance is a financing event, not a fundamental business update, so limited near-term stock impact is expected.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$243.87
T+0 close · Aug 5, 2026 · via day close
Latest settled
+20.92%
T+60 · $294.89
Vs SPY
+22.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $243.87entry
  2. T+1 · 3mo ago +0.89%α +0.28% · $246.04
  3. T+5 · 3mo ago +2.85%α +1.64% · $250.82
  4. T+20 · 3mo ago +6.70%α +6.10% · $260.21
  5. T+60 · 18d ago +20.92%α +22.59% · $294.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AbbVie entered into an underwriting agreement to issue and sell $10.0 billion aggregate principal amount of senior notes across nine tranches, with net proceeds of approximately $9.93 billion. The funds will partially finance the acquisition of Apogee Therapeutics and reduce commitments under a $10.0 billion delayed draw term loan facility. This is a routine debt capital markets transaction for a large investment-grade issuer, increasing leverage but securing financing for a strategic acquisition.

Key Facts

  • AbbVie issued $10.0 billion aggregate principal amount of senior notes across nine tranches with maturities from 2028 to 2066.
  • Net proceeds are expected to be approximately $9.93 billion.
  • Proceeds will fund a portion of the cash payment obligations for the acquisition of Apogee Therapeutics, Inc. and for general corporate purposes.
  • The issuance will reduce commitments under AbbVie's $10.0 billion 364-day delayed draw term loan facility entered into in connection with the Apogee acquisition.
  • The offering is expected to close on August 18, 2026.
  • Interest rates range from Compounded SOFR + 42 bps (floating rate notes) to 6.100% (2066 notes).

Financial Impact

Approximately $9.93 billion in net proceeds raised through a $10.0 billion debt offering.

debtleveragecash

Risk Factors

  • Increased leverage and interest expense from the $10.0 billion debt issuance.
  • Execution risk related to the integration of Apogee Therapeutics and realization of expected synergies.
  • Potential credit rating downgrade if leverage remains elevated post-acquisition.

Market Snapshot

Price
$246.11
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-091269
Document: tm2621452d4_8k.htm0001104659-26-091269
Document: 0001104659-26-091269-index-headers.html0001104659-26-091269
Document: 0001104659-26-091269-index.html0001104659-26-091269
Document: 0001104659-26-091269.txt0001104659-26-091269

Track record

22 reports on ABBV

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $295.03 +0.39% settles Dec 9
  2. Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $295.03 +3.16% settles Dec 2
  3. Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $295.03 +0.05% settles Nov 30
  4. Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $295.03 +0.05% settles Nov 30
  5. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $295.03 +4.37% ▲ +4.20% +7.66% vs SPY
  6. Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $295.03 +3.37% ▲ +3.37% +4.53% vs SPY
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $295.03 +11.31% ▲ +9.26% +12.16% vs SPY
  8. Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $295.03 +12.06% ▲ +8.77% +8.06% vs SPY
  9. Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $295.03 +12.85% ▲ +4.30% +1.33% vs SPY
  10. Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $295.03 +13.38% ▲ +1.00% +2.19% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (12h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026